Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several...
30 insider purchases on record · latest filing 2026-05-20.
Insiders have also filed 15 sale transactions at RLYB.